ALERT COVID-19 | Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3

RVV | RVVTF TORONTO, July 31, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the…

Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases

TORONTO, April 08, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

TORONTO, April 03, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),…

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 30, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 25, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

Revive Therapeutics Ltd. (CSE: RVV) TORONTO, March 24, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive”…

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

TORONTO, March 20, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV),a…